Want to join the conversation?
$OREX 2Q15 Call: In June, Contrave grew to 34.3% share of the branded market vs. $32.9% in May and now is also the growing lead over the other agents. Contrave had strong Rx volume for June, 61,000 prescriptions according to IMS Health, which was up 8% vs. May performance and in 2Q15, total prescription volume was 172,000, up 47% over 1Q15.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.